Related Experiment Video
Updated: Jun 24, 2025
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Lipoprotein(a): Are we ready for large-scale clinical trials?
Shiyue Zheng1, Guangming Fang2, Jie Du2
1Department of Cardiology, Anzhen Hospital, Capital Medical University, Beijing, China.
Insights
Lipoprotein (a) [Lp(a)] is a key risk factor for cardiovascular diseases and calcified aortic valve stenosis. Accurate Lp(a) measurement is crucial for managing this "residual risk" and guiding treatment effectively.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Medicine
Background:
- Cardiovascular diseases (CVD) pose a significant global health threat, often linked to hyperlipidemia.
- Lipoprotein (a) [Lp(a)] is recognized as an independent risk factor for atherosclerotic CVD and calcified aortic valve stenosis.
- Elevated Lp(a) represents an unaddressed
Purpose of the Study:
- To review the structure of Lp(a).
- To discuss current challenges in measuring plasma Lp(a) concentrations.
- To evaluate the impact of existing lipid-lowering therapies on Lp(a).
Main Methods:
- Literature review of Lp(a) structure and function.
- Analysis of current clinical assays for Lp(a) measurement.
- Synthesis of data on lipid-lowering therapies and their effects on Lp(a).
Main Results:
- Lp(a) is a complex lipoprotein with a distinct structure contributing to its atherogenic potential.
- Existing methods for measuring plasma Lp(a) face challenges related to standardization and accuracy.
- Current lipid-lowering therapies show variable effects on Lp(a) levels, necessitating further investigation.
Conclusions:
- Accurate Lp(a) measurement is fundamental for diagnosing and managing high Lp(a) levels.
- Addressing Lp(a) is critical for reducing residual cardiovascular risk.
- Further research is needed to optimize Lp(a) monitoring and therapeutic strategies.
Abstract:
Cardiovascular diseases (CVD) are currently the most important disease threatening human health, which may be due to the high incidence of risk factors including hyperlipidemia. With the deepening of research on lipoprotein, lipoprotein (a) [Lp(a)] has been shown to be an independent risk factor for atherosclerotic cardiovascular diseases and calcified aortic valve stenosis and is now an unaddressed "residual risk" in current CVD management. Accurate measurement of Lp(a) concentration is the basis for diagnosis and treatment of high Lp(a). This review summarized the Lp(a) structure, discussed the current problems in clinical measurement of plasma Lp(a) concentration and the effects of existing lipid-lowering therapies on Lp(a).
